s with the presentation of initial interim 24-week data from the Population Extension cohort of its PRISM Phase 2 cli...

Published | Modified July 17, 2024
CSIMarket Newsroom | CSIMarket.com

4D Molecular Therapeutics: Trailblazing Genetic Medicines for Wet AMD and Cystic Fibrosis

By Author Name

EMERYVILLE, Calif. In what can only be described as a groundbreaking year, 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT) has announced a series of positive interim results from its clinical trials targeting wet Age-related Macular Degeneration (AMD) and cystic fibrosis (CF). As a clinical-stage genetic medicines company, 4DMT is setting new benchmarks in the field, reaffirming its commitment to unlocking the full potential of genetic medicines for treating large-market diseases.

Promising Results from PRISM Phase 2 Clinical Trial for Wet AMD

On July 17, 2024, 4DMT made

Sources for this article: Based on 4d Molecular Therapeutics Inc ’s official statement and Supply Chain Analysis by CSIMarket.com

For details on how CSIMarket validates financial and corporate news, please review our Editorial Standards & Fact-Checking Policy .

Comments

Comments are available to active subscribers. Subscribe or Log in.

Get the full CSIMarket dataset: Subscribe API License